Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EncisionECIA 35 Days Payable is 35.30 as of Sep. 2025, which is 16% below its 10-year median of 42.12. GuruFocus rates ECIA with a GF Score™ of 35/100 and a GF Value™ of $0.34 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 794 Medical Devices & Instruments companies, Encision ranks worse than 71.28% on this metric.
Encision's average Accounts Payable for the
three
months ended in Sep. 2025 was $0.32 Mil. Encision's Cost of Goods Sold for the
three
months ended in Sep. 2025 was $0.83 Mil.
Hence, Encision's Days Payable for the
three
months ended in Sep. 2025 was 35.30.
The historical rank and industry rank for Encision's Days Payable or its related term are showing as below:
ECIA'
s Days Payable Range Over the Past 10 Years
Min: 31.02 Med: 42.12 Max: 50.98
Current: 44.12
During the past 13 years, Encision's highest Days Payable was 50.98. The lowest was 31.02. And the median was 42.12.
ECIA's Days Payable is ranked worse than 71.28% of 794
companies
in the Medical Devices & Instruments industry
Industry Median: 68.505
vs ECIA: 44.12
Encision's Days Payable
increased
from Sep. 2024 (28.99) to Sep. 2025 (35.30).
It may suggest that Encisiondelayed paying its suppliers.
The historical data trend for Encision's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Encision's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Encision Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Encision's Days Payable distribution charts can be found below:
* The bar in red indicates where Encision's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Encision's Days Payable for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Encision (ECIA) has a Days Payable of 35.30 as of Sep. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Encision and its competitors. This is 16% below median its historical median of 42.12. Over the past decade, Encision's Days Payable has ranged from 31.02 to 50.98. According to the industry distribution chart, Encision ranks #566 out of 794 companies in the Medical Devices & Instruments industry, placing it in the top 71.3%.
Is Encision's Days Payable too high?
Encision's current Days Payable of 35.30 is 16% below median its 10-year median of 42.12. Over the past 10 years, this metric has ranged from a low of 31.02 to a high of 50.98. The Medical Devices & Instruments industry median Days Payable is 68.51. Encision's value of 35.30 is 48.5% below this industry median. Based on the distribution chart, Encision ranks #566 out of 794 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Encision has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Encision's Days Payable compare to GCTK and YBGJ?
According to the Medical Devices & Instruments industry distribution chart, Encision ranks #566 out of 794 companies for Days Payable. This places Encision in the lower half of its industry. The industry median Days Payable is 68.51. Encision's value of 35.30 is 48.5% below this benchmark. Historically, Encision's own Days Payable has ranged from 31.02 to 50.98 over the past decade. While the company's 10-year median is 42.12 vs. the industry median of 68.51, Encision has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.51, based on 794 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Encision's current Days Payable of 35.30 is 48.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Encision and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Encision's current Days Payable is 35.30, which is 16% below median its own 10-year median of 42.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Encision stock overvalued right now?
Based on GuruFocus' analysis, Encision (ECIA) is currently considered Possible Value Trap. The stock's GF Value™ is $0.34, compared to a current price of $0.19 — trading 44.1% below its estimated fair value. The current Days Payable is 35.30, which is 16% below median its 10-year median of 42.12 and 48.5% below the Medical Devices & Instruments industry median of 68.51. Encision's overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Encision (ECIA), the current Days Payable is 35.30 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Encision (ECIA) Overvalued in 2026?
Based on GuruFocus' analysis, Encision stock appears to be undervalued.
The current stock price of $0.19 is trading 44.1% below its estimated GF Value™ of $0.34.
GuruFocus considers Encision to be Possible Value Trap.
Key valuation signals for ECIA:
Days Payable: 35.30 (16% below median its 10-year median of 42.12)
GF Value™: $0.34 vs. price of $0.19 (44.1% below fair value)
Industry Position: 48.5% below the Medical Devices & Instruments median (#566 of 794)
No single metric tells the full story. See the ECIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Encision Inc is a medical device company. The company develops and markets technology that provides unprecedented outcomes and patient safety in minimally invasive surgery. The company has established and developed AEM (Active Electrode Monitoring) technology and surgical instruments which provide surgeons with the desired tissue effects of cutting and coagulating tissue in laparoscopic procedures while preventing stray electrosurgical energy that can cause complications and even death. The segments of the company are Product and Service. Product designs develops, manufactures and markets patented surgical instruments. Service performs electrical engineering activities for external entities. Maximum revenue is generated from the product segment.
35GF Score
Get the complete analysis for ECIA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ECIA has been successfully added to your 
